SCHEMBL17565768

SCHEMBL17565768

Cc1ccc(C(O)C(C)NC(C)CCc2ccccc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 5/20 0.80
SLC6A3 Q01959 5/20 0.80
ADRA1A P35348 4/20 0.80
HIF1A Q16665 4/20 0.80
CYP2D6 P10635 4/20 0.80
KCNH2 Q12809 3/20 0.80
OPRM1 P35372 3/20 0.80
OPRK1 P41145 3/20 0.80
ADRB2 P07550 3/20 0.80
HTR1A P08908 2/20 0.80
ADRA2A P08913 2/20 0.80
DRD3 P35462 2/20 0.80
CYP1A2 P05177 2/20 0.80
CYP2C19 P33261 2/20 0.80
MAPK1 P28482 2/20 0.80
CYP3A4 P08684 2/20 0.80
LMNA P02545 2/20 0.80
ADRB1 P08588 2/20 0.80
ADRA2B P18089 1/20 0.80
ADRA2C P18825 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nylidrin SCHEMBL15517085 0.89 HIF1A (1.00) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Nylidrin SCHEMBL159150 0.89 HIF1A (1.00) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Nylidrin SCHEMBL3701975 0.89 HIF1A (1.00) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Nylidrin SCHEMBL364078 0.87 ADRA1A (1.00) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Nylidrin SCHEMBL15512520 0.86 HIF1A (0.95) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Bufeniode SCHEMBL309865 0.80 ADRA1A (0.70) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
SCHEMBL5270601 0.79 MAPK1 (0.66) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
Nylidrin SCHEMBL13724281 0.76 ADRB2 (0.73) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
SCHEMBL9640991 0.75 SIGMAR1 (0.64) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6
SCHEMBL10021106 0.75 PPARG (0.48) SLC6A2SLC6A3ADRA1AHIF1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160067240-A1 NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160067240-A1 NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE GLS, MCL1, TYMS SLC6A2 4677/4885SLC6A3 4041/4885ADRA1A 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.